CD28z CARs and armored CARs Journal Article
| Authors: | Pegram, H. J.; Park, J. H.; Brentjens, R. J. |
| Article Title: | CD28z CARs and armored CARs |
| Abstract: | CD19-targeted chimeric antigen receptor (CAR) T cells are currently being tested in the clinic with very promising outcomes. However, limitations to CAR T cell therapy exist. These include lack of efficacy against some tumors, specific targeting of tumor cells without affecting normal tissue and retaining activity within the suppressive tumor microenvironment. Whereas promising clinical trials are in progress, preclinical development is focused on optimizing CAR design, to generate "armored CAR T cells," which are protected from the inhibitory tumor microenvironment. Studies investigating the expression of cytokine transgenes, combination therapy with small molecule inhibitors, or monoclonal antibodies, are aimed at improving the antitumor efficacy of CAR T cell therapy. Other strategies aimed at improving CAR T cell therapy include using dual CARs and chemokine receptors to more specifically target tumor cells. This review will describe the current clinical data and some novel armored CAR T cell approaches for improving antitumor efficacy therapy. Copyright © 2014 Lippincott Williams & Wilkins. |
| Keywords: | chimeric antigen receptor (car); "armored car t cells"; antitumor efficacy therapy |
| Journal Title: | The Cancer Journal |
| Volume: | 20 |
| Issue: | 2 |
| ISSN: | 1528-9117 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2014-03-01 |
| Start Page: | 127 |
| End Page: | 133 |
| Language: | English |
| DOI: | 10.1097/ppo.0000000000000034 |
| PROVIDER: | scopus |
| PUBMED: | 24667958 |
| PMCID: | PMC4687893 |
| DOI/URL: | |
| Notes: | Export Date: 1 May 2014 -- CODEN: CAJOC -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work